Legal & General Group
EIDX

Legal & General Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Legal & General Group’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,573
Closed -$207K – 3541
2020
Q4 		$207K Sell
1,573
-49
-3% -$4.33K ﹤0.01% 2413
2020
Q3 		$82K Sell
1,622
-476
-23% -$21.4K ﹤0.01% 2544
2020
Q2 		$100K Buy
2,098
+10
+0.5% +$465 ﹤0.01% 2538
2020
Q1 		$102K Sell
2,088
-512
-20% -$26.1K ﹤0.01% 2405
2019
Q4 		$150K Buy
2,600
+704
+37% +$34.9K ﹤0.01% 2472
2019
Q3 		$68K Hold
1,896
– – ﹤0.01% 2642
2019
Q2 		$54K Sell
1,896
-800
-30% -$21.7K ﹤0.01% 2751
2019
Q1 		$63K Buy
2,696
+1,592
+144% +$25.5K ﹤0.01% 2638
2018
Q4 		$15K Hold
1,104
– – ﹤0.01% 3191
2018
Q3 		$11K Buy
+1,104
New +$18.1K ﹤0.01% 3319

Legal & General Group's EIDX Position: Q1 2021 in Review

Legal & General Group sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 1,573 shares — an estimated $207K sold.

Legal & General Group first reported a position in EIDX in Q3 2018 and held it in 10 quarters. The position peaked at $207K in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Legal & General Group reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Legal & General Group sold 1,573 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $207K.
  • Legal & General Group first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 10 quarters.
  • Legal & General Group's Eidos Therapeutics, Inc. Common Stock position peaked at $207K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Legal & General Group's 13F filing for Q1 2021, filed 17 May 2021.